NBTX

Nanobiotix S.A. [NBTX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

NBTX Stock Summary

Top 10 Correlated ETFs

NBTX

Top 10 Correlated Stocks

NBTX

In the News

NBTX Financial details

Company Rating
-
Market Cap
275.43M
Income
-74.13M
Revenue
6.74M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
101
Optionable
No
Shortable
Yes
Earnings
22 Apr 2024
P/E
-4.27
Forward P/E
-
PEG
-0.75
P/S
68.93
P/B
-9
P/C
-
P/FCF
-8.85
Quick Ratio
1.3
Current Ratio
1.38
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.12
EPS next Y
-
EPS next Q
-
EPS this Y
21.48%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
1.53%
Revenue last 5Y
110.34%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
5.56%
SMA50
111.11%
SMA100
280%
Inst Own
-
Inst Trans
-
ROA
-95%
ROE
44740%
ROC
-2.14%
Gross Margin
79%
Oper. Margin
-978%
Profit Margin
-1194%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.75-11.0
52W High
+68.18%
52W Low
+1750%
RSI
48
Rel Volume
4.13
Avg Volume
20.84K
Volume
86.01K
Perf Week
-16.59%
Perf Month
59.9%
Perf Quarter
455.56%
Perf Half Y
479.94%
-
-
-
-
Beta
1.252
-
-
Volatility
1.31%, 4.73%
Prev Close
2.83%
Price
18.5
Change
-0.91%

Something similar

Top by Market Cap
META
AMZN
AAPL
FB2A.DE
NVDA
Top Correlated ETFs
XME
XAD6.MI
GMET
COPX
FAN
Top Correlated Stocks
NANO.PA
0QAV.L
HBM
ERO
NDX1.DE
Similar Market Cap
GUJRAFFIA.NS
CHB.TO
FTN.TO
CNIC.L
USOI

Company Profile

Healthcare Biotechnology
  • Volume Average 20.84K
  • Market Capitalization 275.43M
  • Employee 101
  • CEO Mr. Laurent Levy Ph.D.
  • Headquarters Paris,FR
  • IPO Date 2020-12-11
  • Website https://www.nanobiotix.com

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.